Cardiovascular Biotech Misses MAb Era, Looks Ahead To Gene, Cell Therapy
Executive Summary
Biotechnology R&D in cardiovascular disease slowed in the decade following the approval of the pioneering monoclonal antibody ReoPro, but emerging biotechnologies hold the potential for a resurgence of biologics amidst the small molecules that dominate the current CV pipeline